The use of vascular grafts for bypassing peripheral vascular occlusive conditions is believed to be well known, as is the use of microporous expanded polytetrafluoroethylene (ePTFE) in prosthetic vascular grafts. U.S. Pat. No. 6,436,135 to Goldfarb shows and describes an ePTFE prosthetic vascular graft; U.S. Pat. No. 6,273,912 to Scholz et al. shows and describes a flanged graft for end-to-side anastomosis; U.S. Pat. No. 6,190,590 to Randall et al. shows and describes an apparatus and method for making flanged grafts for end-to-side anastomosis; and the publication entitled, “Venaflo™ Vascular Grafts, Information for Use” shows an ePTFE graft with a modified venous end, each of which is incorporated by reference into this application as if fully set forth herein.
In current clinical practice, a peripheral anastomosis between a bypass prosthesis and a peripheral artery has been performed by either direct anastomosis, interposition of a venous segment at the anastomotic site, anastomosing the prosthesis with a long venous patch sutured into the artery, enlargement of the prosthesis with the anastomotic region using a venous patch, or interposition of a venous cylinder between the prosthesis and the artery. In bypass grafting, it is believed that hemodynamic factors are a major cause of thrombosis and the development of subintimal hyperplasia at the anastomotic site. In particular, hemodynamic phenomena may induce the development of intimal hyperplasia, e.g., occlusive legions that are predominately located at a venous anastomosis, which is believed to adversely affect the longevity of ePTFE grafts. Disturbed flow patterns, e.g., recirculation zones, flow separation and reattachment, development of stagnation points, and the rate of change of shear stress can be amplified due to abnormally high flow rates present in arteriovenous grafts. In the paper entitled “The Importance of Correct Trimming of Venaflo Graft Proven by CFD,” presented at the 4th International Congress of the Vascular Access Society, May 25 to 27, 2005, Berlin, Germany, which is hereby incorporated by reference into this application, Dr. Ulf Krueger describes how graft geometry at the site of a venous anastomosis directly affects hemodynamic factors.
In order to mitigate intimal hyperplasia in an arteriovenous graft, it is known to use a bulb-like shape of the venous end-to-side anastomosis. Preferably, this includes a prefabricated cuff, which is attached to the venous anastomosis, resulting in an enlargement of anastomotic room with a curved vein floor. Flow studies related to the known vascular grafts are believed to suggest that blood flow patterns are optimized compared with previously known non-vascular grafts. However, the positive properties are closely connected with the correct design of the venous anastomosis. The hemodynamic is determined by the anastomotic metrics. Hence, the size and shape of the cuff must closely match the vein diameter in order to realize the aforementioned benefits. The prefabricated cuff, according to the known device, is only roughcast and may be trimmed relative to the vein diameter at maximal dilation by a clinician during surgery. However, if a graft is not trimmed precisely, sub-optimal results may occur.
Leonard Pinchuk, et al., U.S. Pat. No. 4,872,455 (Oct. 10, 1989), shows an anastomosis trimming device that is used for trimming a section of a tubular structure, such as a blood vessel or vascular graft, which is to be anastomosed, to provide an anastomotic end with a smooth, reproducible shape. That is, Pinchuk shows and describes a tool to specifically cut a middle or tubular portion of a graft instead of a flanged or cuffed end of a vascular graft.
Applicants have recognized that precise trimming of a prefabricated flanged end or cuff to achieve optimal blood flow patterns through the cuff can be accomplished through detailed instructions, including trim lines disposed on the cuff and/or through the use of tailoring devices.
Accordingly, described herein is a vascular graft configured to offer optimal geometry for the anastomosis as a function of hemodynamic properties. By optimizing blood flow from the bypass prosthesis to the artery, it is believed that formation of intimal hyperplasia may be reduced with a concomitant increase in graft patency and decreased morbidity.
In one embodiment, the vascular graft includes a generally tubular member and an outwardly flared skirt or cuff that extends circumferentially about the tubular member, the cuff having trim lines and/or sizing indicia thereon. The trim lines indicate the precise size and shape for a cuff, depending on the target vessel to which it is to be attached. Precise trimming along the indicated markings provided directly on the cuff, or on a template to be positioned over the cuff, is believed to result in beneficial blood flow through the vascular graft. In another embodiment, an apparatus for precise trimming of a cuff is described, in which the apparatus includes a base that receives a vascular graft and a template that engages the cuff to guide a surgeon or clinician in trimming a peripheral edge of the cuff according to the size of blood vessel for which the graft is to be attached.
In one embodiment, a vascular graft includes a generally tubular member and a cuff extending from one end of the tubular member, the cuff including an open end spaced from the tubular member, the open end defining an initial outer perimeter having a shape, and a first marking disposed on a surface of the cuff spaced from the open end, the first marking providing an indication for trimming the cuff to a trimmed outer perimeter having a shape different than the shape of the initial outer perimeter.
In another embodiment, a template for a cuff of a vascular graft includes a section of material having a shape of at least a portion of the cuff with an adhesive disposed on a first side thereof and a plurality of markings on a second side thereof, the markings comprising a first trim line and a second trim line spaced from the first trim line. In yet another embodiment, a template for a cuff of a vascular graft includes a pocket including a first side joined to a second side along opposing edges thereof, one of the first side or second side including a first trim line.
In one embodiment, a trimming apparatus includes a base, including a mandrel having a tubular section and a flared section, and a template pivotally attached to the base, including an opening having a configuration of a cuff In another embodiment, an apparatus is provided for trimming a vascular graft suitable for end-to-side anastomosis, the vascular graft including a tubular member and a flared skirt that projects from an end of the tubular member to a formed peripheral edge, the apparatus including a base that receives a portion of the flared skirt of the vascular graft, and a template that projects onto the flared skirt of the vascular graft a guide defining a trimmed peripheral edge of the flared skirt.
In another embodiment, a trimming guide is provided for a vascular graft suitable for end-to-side anastomosis, the vascular graft including a tubular member and a flared skirt, the tubular member having at least one alignment mark extending longitudinally between proximal and distal ends, and the flared skirt projecting from the distal end of the tubular member to a formed peripheral edge, the trimming guide including a first portion being registered with respect to the at least one alignment mark of the tubular member, and a second portion imposing on the flared skirt a guide that defines a trimmed peripheral edge of the flared skirt.
In yet another embodiment, a system of trimming a vascular graft suitable for end-to-side anastomosis is provided, the vascular graft including a tubular member and a flared skirt, the tubular member having a central axis extending between proximal and distal ends, and the flared skirt projecting from the distal end of the tubular member to a formed peripheral edge, the system including a base being registered with respect to the vascular graft, the base including a body engaging the flared skirt and a template imposing on the flared skirt a guide defining a trimmed peripheral edge of the flared skirt, and a cutting implement following the guide to define the trimmed peripheral edge of the flared skirt.
In one embodiment, a method of trimming a vascular graft suitable for end-to-side anastomosis is provided, the vascular graft including a tubular member and a flared skirt that projects from an end of the tubular member to a formed peripheral edge, the method including registering a guide with respect to the vascular graft, projecting the guide on the flared skirt of the vascular graft to define a trimmed peripheral edge of the flared skirt, and cutting the flared skirt to provide the trimmed peripheral edge.
In another embodiment, a method of trimming a vascular graft is provided where the graft has a generally tubular body that defines a longitudinal axis extending through the generally tubular body. The method can be achieved by providing a flared end connected to the generally tubular body; and cutting the flared end along a trimmed perimeter smaller than a generally elliptical boundary having two foci on a common axis, the trimmed perimeter defining a border contiguous to the generally elliptical boundary at a first location disposed on the common axis and at two locations disposed generally symmetrically about the common axis.
In yet another embodiment, a method of attaching a graft to a vessel includes providing a graft, including a tubular portion and a cuff portion extending from the tubular portion, the cuff portion including a first line and a second line disposed on a surface thereof, the first and second lines having the general shape of a peripheral edge of the cuff and being spaced apart from one another, and determining whether to trim the graft along one of the first and second lines based on the size of the vessel.
In one embodiment, a kit for producing a tailored graft, includes a vascular graft having a generally tubular body and an end section, and a tailoring apparatus selected from one or more of: a film having a shape of at least a portion of the end section with an adhesive disposed on a first side thereof and a plurality of markings on a second side thereof; a pocket including a first side joined to a second side along opposing edges thereof, one of the first side or second side including one or more tailoring lines; a cutting device including a base configured to engage the end section, a template defining a tailoring perimeter, and a cutting implement positioned along the tailoring perimeter; and, a trimming device including a mandrel with a tubular section and a flared section, and a template with an opening shaped in the form of a predetermined shape for the end section, the opening including a cutting edge along a perimeter thereof.
These and other embodiments, features and advantages will become apparent to those skilled in the art when taken with reference to the following more detailed description of the invention in conjunction with the accompanying drawings that are first briefly described.
The following detailed description should be read with reference to the drawings, in which like elements in different drawings are identically numbered. The drawings, which are not necessarily to scale, depict selected embodiments and are not intended to limit the scope of the invention. The detailed description illustrates by way of example, not by way of limitation, the principles of the invention. This description will clearly enable one skilled in the art to make and use the invention, and describes several embodiments, adaptations, variations, alternatives and uses of the invention, including what is presently believed to be the best mode of carrying out the invention.
One embodiment of a vascular cuff graft is illustrated in
The cuff 56 in the embodiment shown in
Bioactive agents may be incorporated into the vascular cuff graft 50, including, but not limited to, activated charcoal, carbon particles, graphite particles, vasodilator, anti-coagulants, such as, for example, warfarin and heparin. Other bio-active agents can also include, but are not limited to agents such as, for example, anti-proliferative/antimitotic agents including natural products such as vinca alkaloids (i.e. vinblastine, vincristine, and vinorelbine), paclitaxel, epidipodophyllotoxins (i.e. etoposide, teniposide), antibiotics (dactinomycin (actinomycin D) daunorubicin, doxorubicin and idarubicin), anthracyclines, mitoxantrone, bleomycins, plicamycin (mithramycin) and mitomycin, enzymes (L-asparaginase which systemically metabolizes L-asparagine and deprives cells which do not have the capacity to synthesize their own asparagine); antiplatelet agents such as G(GP) IIb/IIIa inhibitors and vitronectin receptor antagonists; anti-proliferative/antimitotic alkylating agents such as nitrogen mustards (mechlorethamine, cyclophosphamide and analogs, melphalan, chlorambucil), ethyl enimines and methylmelamines (hexamethylmelamine and thiotepa), alkyl sulfonates-busulfan, nirtosoureas (carmustine (BCNU) and analogs, streptozocin), trazenes-dacarbazinine (DTIC); anti-proliferative/antimitotic antimetabolites such as folic acid analogs (methotrexate), pyrimidine analogs (fluorouracil, floxuridine, and cytarabine), purine analogs and related inhibitors (mercaptopurine, thioguanine, pentostatin and 2-chlorodeoxyadenosine {cladribine}); platinum coordination complexes (cisplatin, carboplatin), procarbazine, hydroxyurea, mitotane, aminoglutethimide; hormones (i.e. estrogen); anti-coagulants (heparin, synthetic heparin salts and other inhibitors of thrombin); fibrinolytic agents (such as tissue plasminogen activator, streptokinase and urokinase), aspirin, dipyridamole, ticlopidine, clopidogrel, abciximab; antimigratory; antisecretory (breveldin); anti-inflammatory: such as adrenocortical steroids (cortisol, cortisone, fludrocortisone, prednisone, prednisolone, 6α-methylprednisolone, triamcinolone, betamethasone, and dexamethasone), non-steroidal agents (salicylic acid derivatives i.e. aspirin; para-aminophenol derivatives i.e. acetominophen; indole and indene acetic acids (indomethacin, sulindac, and etodalac), heteroaryl acetic acids (tolmetin, diclofenac, and ketorolac), arylpropionic acids (ibuprofen and derivatives), anthranilic acids (mefenamic acid, and meclofenamic acid), enolic acids (piroxicam, tenoxicam, phenylbutazone, and oxyphenthatrazone), nabumetone, gold compounds (auranofin, aurothioglucose, gold sodium thiomalate); immunosuppressives: (cyclosporine, tacrolimus (FK-506), sirolimus (rapamycin), azathioprine, mycophenolate mofetil); angiogenic agents: vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF); angiotensin receptor blockers; nitric oxide donors; anti-sense oligionucleotides and combinations thereof; cell cycle inhibitors, mTOR inhibitors, and growth factor receptor signal transduction kinase inhibitors; retenoids; cyclin/CDK inhibitors; HMG co-enzyme reductase inhibitors (statins); and protease inhibitors.
The vascular cuff graft 50 may include an alignment guide that is printed or otherwise marked on an outer surface of the tubular member 52. The alignment guide in the embodiment shown in
Markings, such as trim lines 64 and 65, are positioned on a top surface of the cuff 56 to provide alternatives to a vascular surgeon for tailoring the size of the cuff 56, depending on the vessel to which it is to be attached. In the embodiment shown in
Preferred formulations for inks provide different colors. For example, a bright cobalt blue line at 33% urethane is provided by dissolving three grams urethane in 17 grams THF (a 12% solution is preferable), then mixing in 1.0 grams cobalt blue. A dark blue line that is an FDA safe mixture includes FD&C #2 at 1% of urethane and cobalt blue at 2% urethane, which is provided by dissolving 0.3 grams FD&C #2 in 15 grams of water and heating to approximately 150 degrees C.; adding 20 grams of DMAc to the water solution, making an azeotrope, and shaking well; adding 15 grams of urethane to 85 grams of THF and dissolving thoroughly (15% solution); adding 3.5 grams of the DMAc water solution to the 100 grams of the urethane/THF solution; and adding 0.3 grams cobalt blue to the resulting solution and shaking well. Commercially available inks may also be used. For example, TPR Ink manufactured by Marabuwerke GmbH & Co. (Tamm, Germany), is available from Autoroll Print Technologies, LLC (Middleton, Mass.; part number 3803 57 980). As a thinner for the TPR Ink, TPV Thinner, also manufactured by Marabuwerke GmbH & Co., is also available from Autoroll Print Technologies, LLC (part number 3501 97 046). Also, TPU ink, manufactured by Marabuwerke GmbH & Co., may be used.
An integral cuff 56 may be formed, for example, by any of a variety of methods known to one skilled in the art, such as, for example, using the apparatus and method described in U.S. Pat. No. 6,190,590 to Randall et al. Referring to
In addition to trim lines on a surface thereof, the cuff may include printed indicia as shown in
By virtue of the various embodiments described herein, a method of trimming a vascular graft is realized. In such method, the graft has a generally tubular body that defines a longitudinal axis extending through the generally tubular body. The method can be achieved by providing a flared end connected to the generally tubular body, shown here in
As discussed above, known vascular grafts with a bulbous-like flange or cuff are believed to lead to an enlargement of anastomotic room with a curved vein floor when attached to a vein in an end-to-side anastomotic procedure. Simulated flow studies related to these cuff grafts suggest that blood flow patterns are optimized in comparison to other prior grafts. However, the positive properties associated with the cuff graft are closely tied to the correct design of the venous anastomosis. Regardless of the manufactured size and shape, the cuff generally must be trimmed somewhat prior to attachment to a vein. However, even in instances when trimming instructions are provided, if the trimming advice is not followed exactly and the cuff not trimmed precisely on the dotted lines or markings indicated, there is believed to be an increased risk of sub-optimal results, one of which is the formation of a hooded region proximate the attachment point of the toe.
Referring back to
The study presented in the paper entitled “The Importance of Correct Trimming of Venaflo Graft Proven by CFD,” presented at the 4th International Congress of the Vascular Access Society, May 25 to 27, 2005, Berlin, Germany, describes how graft geometry at the site of a venous anastomosis directly affects hemodynamic factors. In particular, the study found that the precise trimming of a cuff along modified lines, such as lines 33, 34 and 35 in cuff graft 30, and particularly in predefined perimeters 44, 45, and 46 resulted in measurable advantages over cuff grafts with untrimmed conventional bulb-like cuff configurations and/or cuffs that were not precisely trimmed according to the vein diameter at maximum dilation of the target vein. Such advantages include an enlarged anastomotic room, leading to durable flow separation and a prolonged three-dimensional vortex with clockwise rotation, a reduction of pressure rise due to fluid stagnation at the vein floor, and reduced shear stress on the vein floor (which is believed to lead to delayed, reduced or elimination of intimal hyperplasia and venous anastomotic stenosis). Thus, it is believed that precise trimming of a cuff graft, according to the particular perimeter shown and described herein, imparts surprising benefits to the cuff graft at least with respect to the advantages mentioned.
In another embodiment, rather than printing indicia and/or trim lines on a surface of the cuff of a cuff graft, a sizing template may be provided for a conventional cuff graft to enable precise trimming of the cuff to achieve the advantages discussed above.
As shown in
The template 80 may be positioned over a cuff prior to packaging and sold together as a unit, or may be packaged separately from a cuff such that it must be placed over the cuff prior to trimming by a surgeon as described above. In one embodiment, the template 80 is halved such that it is configured to be placed over only a portion of the cuff 22. Thus, the cuff 22 is first folded in half along a line of symmetry prior to attaching a half-sized template 90 with adhesive backing, shown in
In another embodiment, shown in
Opposing tabs 106, each positioned on one side of an inserted cuff graft 20, are provided on the pocket 100 to facilitate removal of the pocket 100 following the trimming of the cuff 22. In the embodiment shown, the pocket 100 is rectangular; however, the pocket may be in any shape including the shape of the cuff 22. The pocket 100 may be positioned over a cuff 22 of a cuff graft 20 and sold as a unit, or may be sold or packaged separately for assembly by an end user. When sold as a unit, the cuff 22 is secured within the pocket 100 such that cutting along the trim lines results in an optimal size and shape of the cuff 22 for attaching to a blood vessel of desired size. The cuff 22 may be secured, for example, by shrinking slightly the material of the pocket 100, by sizing the pocket 100 slightly smaller than the cuff 22 so that the toe and side edge are sealed into the edges of the pocket 100, by applying a thin coat of medical grade lubricant to the inside of the pocket in order to contact the top of the cuff to adhere the cuff 22 to the pocket 100, or other methods known to one skilled in the art. In another embodiment, a half-sized pocket is provided to accommodate a cuff 22 that has been folded along a line of symmetry. This pocket would have partial markings, including a template with trim lines and/or indicia, similar to the half-sized template described above.
In another embodiment illustrated in
Pivotally attached (e.g., via a hinge, etc.) to the base 122 along an edge 123 adjacent a toe portion of the flared section 128 is a template 130. The template 130 includes an opening 132 configured in the desired pattern for a cuff of a cuff graft to achieve optimal flow conditions for a particular diameter vessel, as discussed above. Thus, in one embodiment, the opening 132 includes a section with opposing convex portions to create opposing concave portions on the cuff 22 of a cuff graft 20 positioned over the mandrel 124 (e.g.,
In the example shown in
In another embodiment, the opening 132 is adjustable, depending on the size and shape desired. For example, the opening 132 may include an adjustable edge or surface that can be slid or moved into a desired position depending on the diameter of the vessel to which the cuff 22 is to be attached. Settings could be provided for each of a number of different diameter vessels and each setting could include a locking mechanism. For example, the opening 132 may have an adjustable edge with settings for a 3-5 mm diameter vessel and a 6-8 diameter vessel, assuming that the original opening 132 is configured to correspond to an optimal shape and size for attaching to a 9-10 diameter vessel. Thus, to adjust the edge for a smaller diameter vessel, a locking pin or like mechanism could be adjusted to move the edge inward. The adjustable edge could include numeric indicia on a surface thereof to indicate to a user the diameter of vessel for each setting. In one embodiment, the cutout member is adjustable to provide the ability to trim to several different sizes and shapes of cuffs based on need, the cutout member having an outside surface and contour that mates with the inside surface of the opening 132, and an inside surface that can be adjusted to different shapes and/or sizes.
This invention has been described and specific examples of the invention have been portrayed. While the invention has been described in terms of particular variations and illustrative figures, those of ordinary skill in the art will recognize that the invention is not limited to the variations or figures described. In addition, where methods and steps described above indicate certain events occurring in certain order, those of ordinary skill in the art will recognize that the ordering of certain steps may be modified and that such modifications are in accordance with the variations of the invention. Additionally, certain of the steps may be performed concurrently in a parallel process when possible, as well as performed sequentially as described above. Therefore, to the extent there are variations of the invention, which are within the spirit of the disclosure or equivalent to the inventions found in the claims, it is the intent that this patent will cover those variations as well. Finally, all publications and patent applications cited in this specification are herein incorporated by reference in their entirety as if each individual publication or patent application were specifically and individually put forth herein.
This application is a division of U.S. patent application Ser. No. 14/228,995, filed Mar. 28, 2014, now U.S. Pat. No. 9,532,865, which is a division of U.S. patent application Ser. No. 11/408,330, filed Apr. 21, 2006, now U.S. Pat. No. 8,709,069, which claims the benefit under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 60/695,406, filed Jul. 1, 2005, each of which is incorporated by reference into this application as if fully set forth herein.
Number | Name | Date | Kind |
---|---|---|---|
2127903 | Bowen | Aug 1938 | A |
3196194 | Ely, Jr. et al. | Jul 1965 | A |
3492994 | Field | Feb 1970 | A |
3683926 | Suzuki | Aug 1972 | A |
3713441 | Thomas | Jan 1973 | A |
3805301 | Liebig | Apr 1974 | A |
3815608 | Spinosa et al. | Jun 1974 | A |
3816919 | Portnoy | Jun 1974 | A |
3818511 | Goldberg et al. | Jun 1974 | A |
3825257 | Palmer | Jul 1974 | A |
3826257 | Buselmeier | Jul 1974 | A |
3853462 | Smith | Dec 1974 | A |
3882862 | Berend | May 1975 | A |
3945052 | Liebig | Mar 1976 | A |
3986828 | Hoffman, Jr. et al. | Oct 1976 | A |
4047252 | Liebig et al. | Sep 1977 | A |
4098571 | Miyata et al. | Jul 1978 | A |
4192312 | Wilson | Mar 1980 | A |
4234535 | Okita | Nov 1980 | A |
4279259 | Lee et al. | Jul 1981 | A |
4309776 | Berguer | Jan 1982 | A |
4313231 | Koyamada | Feb 1982 | A |
4321914 | Begovac et al. | Mar 1982 | A |
4345414 | Bornat et al. | Aug 1982 | A |
4354495 | Bodicky | Oct 1982 | A |
4366819 | Kaster | Jan 1983 | A |
4387516 | Laux | Jun 1983 | A |
4416028 | Eriksson et al. | Nov 1983 | A |
4441215 | Kaster | Apr 1984 | A |
4482516 | Bowman et al. | Nov 1984 | A |
4501263 | Harbuck | Feb 1985 | A |
4503568 | Madras | Mar 1985 | A |
4517687 | Liebig et al. | May 1985 | A |
4530113 | Matterson | Jul 1985 | A |
4561129 | Arpesella | Dec 1985 | A |
4601718 | Possis et al. | Jul 1986 | A |
4630375 | Spolyar | Dec 1986 | A |
4712551 | Rayhanabad | Dec 1987 | A |
4714421 | D'Agostino | Dec 1987 | A |
4728328 | Hughes et al. | Mar 1988 | A |
4743480 | Campbell et al. | May 1988 | A |
4807622 | Ohkaka et al. | Feb 1989 | A |
4816028 | Kapadia et al. | Mar 1989 | A |
4840940 | Sottiurai | Jun 1989 | A |
4872455 | Pinchuk et al. | Oct 1989 | A |
4883453 | Berry et al. | Nov 1989 | A |
4909979 | Possis et al. | Mar 1990 | A |
4935190 | Tennerstedt | Jun 1990 | A |
4944737 | Bloom | Jul 1990 | A |
4957508 | Kaneko et al. | Sep 1990 | A |
4957669 | Primm | Sep 1990 | A |
5042161 | Hodge | Aug 1991 | A |
5078735 | Mobin-Uddin | Jan 1992 | A |
5100422 | Berguer et al. | Mar 1992 | A |
5110526 | Hayashi et al. | May 1992 | A |
5156619 | Ehrenfeld | Oct 1992 | A |
5304340 | Downey | Apr 1994 | A |
D348618 | Leslie et al. | Jul 1994 | S |
5376110 | Tu et al. | Dec 1994 | A |
5387236 | Noishiki et al. | Feb 1995 | A |
5399352 | Hanson | Mar 1995 | A |
5443497 | Venbrux | Aug 1995 | A |
5456712 | Maginot | Oct 1995 | A |
5456714 | Owen | Oct 1995 | A |
5472404 | Volgushev | Dec 1995 | A |
5476506 | Lunn | Dec 1995 | A |
5496341 | Sauer et al. | Mar 1996 | A |
5500014 | Quijano et al. | Mar 1996 | A |
5575817 | Martin | Nov 1996 | A |
5591203 | Fahy | Jan 1997 | A |
5653743 | Martin | Aug 1997 | A |
5683449 | Marcade | Nov 1997 | A |
5695504 | Gifford, III et al. | Dec 1997 | A |
5713859 | Finch, Jr. et al. | Feb 1998 | A |
5723005 | Herrick | Mar 1998 | A |
5752934 | Campbell et al. | May 1998 | A |
5755779 | Horiguchi | May 1998 | A |
5755780 | Finch, Jr. et al. | May 1998 | A |
5782916 | Pintauro et al. | Jul 1998 | A |
5814005 | Barra et al. | Sep 1998 | A |
5824010 | McDonald | Oct 1998 | A |
5827327 | McHaney et al. | Oct 1998 | A |
5843158 | Lenker et al. | Dec 1998 | A |
5843165 | Plaia et al. | Dec 1998 | A |
5849036 | Zarate | Dec 1998 | A |
5861026 | Harris et al. | Jan 1999 | A |
5893886 | Zegdi et al. | Apr 1999 | A |
5902317 | Kleshinski et al. | May 1999 | A |
5950320 | Dorsey | Sep 1999 | A |
5976159 | Heartport | Nov 1999 | A |
5989287 | Yang et al. | Nov 1999 | A |
6019788 | Butters et al. | Feb 2000 | A |
6039754 | Caro | Mar 2000 | A |
6048362 | Berg | Apr 2000 | A |
6056717 | Finch et al. | May 2000 | A |
6086553 | Akbik | Jul 2000 | A |
6102884 | Squitieri | Aug 2000 | A |
6136022 | Nunez et al. | Oct 2000 | A |
6187033 | Schmitt et al. | Feb 2001 | B1 |
6190590 | Randall et al. | Feb 2001 | B1 |
6193746 | Strecker | Feb 2001 | B1 |
6203735 | Edwin et al. | Mar 2001 | B1 |
6210430 | Solem | Apr 2001 | B1 |
6221101 | Harris et al. | Apr 2001 | B1 |
6273912 | Scholz | Aug 2001 | B1 |
6371981 | Yang et al. | Apr 2002 | B1 |
6436135 | Goldfarb | Aug 2002 | B1 |
6458155 | Van Nguyen et al. | Oct 2002 | B1 |
6554856 | Doorly et al. | Apr 2003 | B1 |
6582409 | Squitieri | Jun 2003 | B1 |
6585762 | Stanish | Jul 2003 | B1 |
6589278 | Harris et al. | Jul 2003 | B1 |
6613087 | Healy et al. | Sep 2003 | B1 |
6626865 | Prisell | Sep 2003 | B1 |
6626939 | Burnside et al. | Sep 2003 | B1 |
6746480 | Scholz et al. | Jun 2004 | B2 |
6767358 | Leonhardt et al. | Jul 2004 | B2 |
6821295 | Farrar | Nov 2004 | B1 |
6857196 | Dalrymple | Feb 2005 | B2 |
6858035 | Whayne | Feb 2005 | B2 |
7553316 | Scholz et al. | Jun 2009 | B2 |
8709069 | Scholz et al. | Apr 2014 | B2 |
9532865 | Scholz | Jan 2017 | B2 |
20020193872 | Trout et al. | Dec 2002 | A1 |
20030014108 | Lauren | Jan 2003 | A1 |
20030051362 | Buckman et al. | Mar 2003 | A1 |
20030182815 | Carlson | Oct 2003 | A1 |
20040039453 | Anderson et al. | Feb 2004 | A1 |
20040064181 | Harris et al. | Apr 2004 | A1 |
20040210302 | Scholz et al. | Oct 2004 | A1 |
20050055079 | Duran | Mar 2005 | A1 |
20050272806 | Falotico et al. | Dec 2005 | A1 |
20060030935 | Scholz et al. | Feb 2006 | A1 |
20060210816 | Finley | Sep 2006 | A1 |
20070005128 | Scholz et al. | Jan 2007 | A1 |
20070255400 | Parravicini et al. | Nov 2007 | A1 |
20100280598 | Fox | Nov 2010 | A1 |
20140208913 | Scholz et al. | Jul 2014 | A1 |
Number | Date | Country |
---|---|---|
0269254 | Jun 1988 | EP |
63158052 | Jul 1988 | JP |
1995009585 | Apr 1995 | WO |
1995014442 | Jun 1995 | WO |
1995034255 | Dec 1995 | WO |
1996000103 | Jan 1996 | WO |
1997031591 | Sep 1997 | WO |
1998052495 | Nov 1998 | WO |
Entry |
---|
Advertisement for FEP-Ringed Gore-TEX Vascular Graft, 1 page, prior to Jun. 21, 1989. |
Bard Peripheral Vascular, Inc., Venaflo Vascular Grafts Information for Use, Rev. 2, 10/104, 2004. |
Bard Peripheral Vascular, Inc.; “Hemodynamics and Cuff Technology”, 2005. |
Batson, R.C., M.D. et al; “Linton Patch Angioplasty”, Ann. Surg., pp. 684-693, vol. 199, No. 6, Jun. 1984. |
Beard, J.D. et al, Haemodynamics of the Interposition Vein Cuff, Sr. J. Surg, vol. 73, No. 10, pp. 823-825, Oct. 1986. |
Chester et al, “Interposition Vein Patches for Vascular Reconstruction”, pp. 1-3, Feb. 1993. |
Crawshaw et al, “Flow Disturbance at the Distal End-ta-Side Anastomosis”, Arch Surg, vol. 115, pp. 1280-1284, Nov. 1980. |
Da Silva, A.F. et al, “Stable Vortices Within Vein Cuffs Inhibit Anastomotic Myointimal Hyperplasia”, Eur J Vase Sura, vol. 14, pp. 157-163, 1997. |
Dobrin et al, “Mechanical factors predisposing to intimal hyperplasia and medial thickening in autoaenous vein arafts”, Surgery, vol. 105, No. 3, pp. 393-400, Mar. 1989. |
EP 98921634.6 filed May 15, 2008 Office Action dated May 5, 2004. |
EP 98921634.6 filed May 15, 2008 Office Action dated Oct. 10, 2004. |
Escobar, Francisco S. III et al, “Comparison of a New Hooded Graft With a Conventional ePTFE Graft: A Preliminary Study”, Vascular Access for Hemodialysis VI, pp. 205-212, 1999. |
Fillinger et al, “Beneficial Effects of Banding on Venous Intimal-Medial Hyperplasia in Arteriovenous Loop Grafts”; The American Journal of Surgery, vol. 158, pp. 87-94, Aug. 1989. |
Fillinger et al, “Graft Geometry and Venous Intimal-Medial Hyperplasia in Arteriovenous Loop Grafts”, Journal of Vascular Surgery, vol. 11, No. 4, pp. 556-566, Apr. 1990. |
Fisher, R.K. et al, “Harnessing Haemodynamic Forces for the Suppression of Anastomotic Intimal Hyperplasia: the Rationale for Precuffed Grafts”, Eur J Vase Endovasc Surg, vol. 21, pp. 520-528, 2001. |
Gagne, P. J. et al, “The Effect of a Venous Anastomosis Tyrell Vein Collar on the Primary Patency of Arteriovenous Grafts in Patients Undergoing Hemodialysis”, J Vase Surg, vol. 32, No. 6, pp. 1149-1154, 2000. |
Green, R. M. et al, “Prosthetic Above-Knee Femoropopliteal Bypass Grafting: Five-Year Results of a Randomized Trial”, J Vasc Surg, vol. 31, No. 3, pp. 417-425, Mar. 2000. |
Harris, Peter et al, “Haemodynamics of Cuffed Arterial Anastomoses”, Critical Ischaemia, vol. 9, No. 1, pp. 20-26, 1999. |
How, T. V. et al, “Interposition Vein Cuff Anastomosis Alters Wall Shear Stress Distribution in the Recipient Artery”, J Vasc Surg, vol. 31, No. 5, pp. 1008-1017, May 2000. |
Impra, Inc, “Suturing Technique for Venaflo ePTFE Vascular Graft & Venaflo Graft with Carbon”, 1998. |
Impra, Inc, “Tunneling Technique for Venaflo ePTFE Vascular Graft & Venaflo Graft with Carbon”, 1999. |
Jamieson, et al, “Vascular Surgery”, 5th Edition, ISBN 04 12586 304, pp. 330-340, 1994. |
JP 2006-303732 Office Action dated Jun. 2, 2009. |
Krueger et al, “Importance of Correct Trimming of Venaflo Grafts Proven by CFD”, 4th International Congress of the Vascular Access Society, Berlin, Germany, May 25, 2005. |
Lei, Ming et al, “Computational Design of a Bypass Graft That Minimizes Wall Shear Stress Gradients in the Region of the Distal Anastomosis”, Journal of Vascular Surgery, vol. 25, No. 4, pp. 637-646, Apr. 1997. |
Lemson, M.S. et al, “Effects of a Venous Cuff at the Venous Anastomosis of Polytetrafluoroethylene Grafts for Femodialysis Vascular Access”, J Vasc Surg, vol. 32, No. 6, pp. 1155-1163, Dec. 2000. |
Loh, A. et al, “PTFE Bypass Grafting to Isolated Popliteal Segments in Critical Limb Ischaemia”, Eur J Vasc Sur, vol. 7, pp. 26-30, Jan. 1993. |
Miller et al, “The use of the vein cuff and PTFE” In: Greenhalgh RM, ed. Vascular Surgical Techniques. An Atlas. 2nd ed. London: W.B. Saunders, 1989; 276-86. |
Nyberg et al, “Preliminary Experience with a Cuffed ePTFE Graft for Hemodialysis Vascular Access”, Asaio Journel, vol. 47, No. 4, pp. 333-337, Jul./Aug. 2001. |
Panneton, J. M., MD., “Multicenter Randomized Prospective Trial Comparing a Pre-Cuffed Polytetrafluoroethylene Graft to a Vein Cuffed Polytetrafluoroethylene Graft for Infragenicular Arterial Bypass”, Ann Vasc Sura, vol. 18, pp. 199-206, Mar. 15, 2004. |
PCT/GB1998/001418 filed May 15, 1998 International Preliminary Examination Report dated Aug. 25, 1999. |
PCT/GB1998/001418 filed May 15, 1998 International Search Report dated Sep. 2, 1998. |
PCT/GB1998/001418 filed May 15, 1998 Written Opinion dated Sep. 2, 1998. |
PCT/US2008/088312 filed Dec. 24, 2008 Search Report dated Feb. 13, 2009. |
PCT/US2008/088312 filed Dec. 24, 2008 Written Opinion dated Feb. 13, 2009. |
Dueen Elisabeth Hospital Berlin, “Documentation of Comparative Flow Investigations of the Conventional Anastomosis and ‘Venaflo II’ Anastomosis by a Pulsatile Circulating Model”. |
Scholz, Hans M.D. et al, “Five Years' Experience With an Arteriovenous Patch Prosthesis as Access for Hemodialysis”, Vascular Access for Hemodialysis VI, pp. 241-254, 1999. |
Sivanesan, S. et al, “Flow Patterns in the Radiocephalic Arteriovenous Fistular: An in Intro Study”, J Biomech, vol. 32, pp. 915-925, 1999. |
Sorom, AJ. et al, “Prospective, Randomized Evaluation of a Cuffed Expanded Polytetrafluoroethylene Graft for Hemodialysis Vascular Access”, Surgery, vol. 132, No. 2, Aug. 2002. |
Stonebridge, P.A. et al, “Randomized Trial Comparing Infrainguinal Polytetrafluoroethylene Bypass Grafting With and Without Vein Interpostion Cuff at the Distal Anastomosis”, J Vasc Sur, vol. 26, No. 4, pp. 543-550, Oct. 1997. |
Taylor et al, “Improved Technique for Polytetraflouroethylene Bypass Grafting: Long-Term Results Using Anastomotic Vein Patches”, The British Journal of Surgery 1992, vol. 79, pp. 348-354, Apr. 4, 1992. |
Tyrrell, M.R. et al, “New Prosthetic Venous Collar Anastomotic Technique: Combining the Best of Other Procedures”, British J Sur, vol. 78, pp. 1016-1017, Aug. 1991. |
U.S. Appl. No. 10/603,952, filed Jun. 25, 2003 Final Office Action dated Sep. 18, 2014. |
U.S. Appl. No. 10/603,952, filed Jun. 25, 2003 Non-Final Office Action dated May 10, 2013. |
U.S. Appl. No. 10/603,952, filed Jun. 25, 2003 Advisory Action dated Dec. 24, 2013. |
U.S. Appl. No. 10/603,952, filed Jun. 25, 2003 Advisory Action dated Dec. 3, 2010. |
U.S. Appl. No. 10/603,952, filed Jun. 25, 2003 Advisory Action dated Jan. 6, 2015. |
U.S. Appl. No. 10/603,952, filed Jun. 25, 2003 Advisory Action dated Jun. 8, 2006. |
U.S. Appl. No. 10/603,952, filed Jun. 25, 2003 Advisory Action dated Sep. 4, 2007. |
U.S. Appl. No. 10/603,952, filed Jun. 25, 2003 Decision on Appeal dated Jan. 16, 2013. |
U.S. Appl. No. 10/603,952, filed Jun. 25, 2003 Final Office Action dated Apr. 16, 2007. |
U.S. Appl. No. 10/603,952, filed Jun. 25, 2003 Final Office Action dated Feb. 17, 2006. |
U.S. Appl. No. 10/603,952, filed Jun. 25, 2003 Final Office Action dated Oct. 16, 2013. |
U.S. Appl. No. 10/603,952, filed Jun. 25, 2003 Final Office Action dated Oct. 18, 2004. |
U.S. Appl. No. 10/603,952, filed Jun. 25, 2003 Final Office Action dated Sep. 16, 2010. |
U.S. Appl. No. 10/603,952, filed Jun. 25, 2003 Non-Final Office Action dated Apr. 22, 2004. |
U.S. Appl. No. 10/603,952, filed Jun. 25, 2003 Non-Final Office Action dated Apr. 6, 2010. |
U.S. Appl. No. 10/603,952, filed Jun. 25, 2003 Non-Final Office Action dated Aug. 31, 2006. |
U.S. Appl. No. 10/603,952, filed Jun. 25, 2003 Non-Final Office Action dated Feb. 26, 2014. |
U.S. Appl. No. 10/603,952, filed Jun. 25, 2003 Non-Final Office Action dated Mar. 4, 2005. |
U.S. Appl. No. 10/603,952, filed Jun. 25, 2003 Non-Final Office Action dated Oct. 15, 2009. |
U.S. Appl. No. 10/842,582, filed May 10, 2004 Final Office Action dated Dec. 31, 2008. |
U.S. Appl. No. 10/842,582, filed May 10, 2004 Non-Final Office Action dated Jul. 5, 2007. |
U.S. Appl. No. 10/842,582, filed May 10, 2004 Non-Final Office Action dated Nov. 16, 2007. |
U.S. Appl. No. 11/239,416, filed Sep. 30, 2005 Advisory Action dated Feb. 13, 2014. |
U.S. Appl. No. 11/239,416, filed Sep. 30, 2005 Final Office Action dated Dec. 5, 2011. |
U.S. Appl. No. 11/239,416, filed Sep. 30, 2005 Final Office Action dated Mar. 25, 2010. |
U.S. Appl. No. 11/239,416, filed Sep. 30, 2005 Final Office Action dated Oct. 24, 2014. |
U.S. Appl. No. 11/239,416, filed Sep. 30, 2005 Non-Final Office Action dated Apr. 11, 2014. |
U.S. Appl. No. 11/239,416, filed Sep. 30, 2005 Non-Final Office Action dated Jun. 7, 2013. |
U.S. Appl. No. 11/239,416, filed Sep. 30, 2005 Non-Final Office Action dated Sep. 18, 2009. |
U.S. Appl. No. 11/408,330, filed Apr. 21, 2006 Advisory Action dated Nov. 23, 2010. |
U.S. Appl. No. 11/408,330, filed Apr. 21, 2006 Final Office Action dated Oct. 17, 2012. |
U.S. Appl. No. 11/408,330, filed Apr. 21, 2006 Final Office Action dated Sep. 14, 2010. |
U.S. Appl. No. 11/408,330, filed Apr. 21, 2006 Non-Final Office Action dated Jun. 28, 2013. |
U.S. Appl. No. 11/408,330, filed Apr. 21, 2006 Non-Final Office Action dated Mar. 24, 2010. |
U.S. Appl. No. 11/408,330, filed Apr. 21, 2006 Non-Final Office Action dated Mar. 29, 2012. |
U.S. Appl. No. 11/408,330, filed Apr. 21, 2006 Non-Final Office Action dated Sep. 28, 201t. |
U.S. Appl. No. 12/810,822, filed Jun. 25, 2010 Final Office Action dated Sep. 28, 2012. |
U.S. Appl. No. 12/810,822, filed Jun. 25, 2010 Non-Final Office Action dated Apr. 13, 2012. |
Wells et al, “Effect of carotid artery geometry on the magnitude and distribution of wall shear stress gradients”, Journal of Vascular Surgery, vol. 23, No. 4, pp. 667-678, Apr. 1996. |
Wolfe, John H. N., “Polytetrafiuoroethylene (PTFE) Femorodistal Bypass”, Rob & Smith's Operative Surgery/Vascular Surgery, Fifth Edition, pp. 330-340, Sep. 4, 1998. |
Number | Date | Country | |
---|---|---|---|
20170065399 A1 | Mar 2017 | US |
Number | Date | Country | |
---|---|---|---|
60695406 | Jul 2005 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14228995 | Mar 2014 | US |
Child | 15357659 | US | |
Parent | 11408330 | Apr 2006 | US |
Child | 14228995 | US |